JP2023082042A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023082042A5 JP2023082042A5 JP2023045583A JP2023045583A JP2023082042A5 JP 2023082042 A5 JP2023082042 A5 JP 2023082042A5 JP 2023045583 A JP2023045583 A JP 2023045583A JP 2023045583 A JP2023045583 A JP 2023045583A JP 2023082042 A5 JP2023082042 A5 JP 2023082042A5
- Authority
- JP
- Japan
- Prior art keywords
- alkylene
- alkyl
- cycloalkyl
- membered heterocycloalkyl
- membered heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002947 alkylene group Chemical group 0.000 claims 60
- 125000000217 alkyl group Chemical group 0.000 claims 46
- -1 -OH Chemical group 0.000 claims 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims 28
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000001424 substituent group Chemical group 0.000 claims 20
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000001188 haloalkyl group Chemical group 0.000 claims 15
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 14
- 125000003342 alkenyl group Chemical group 0.000 claims 12
- 125000000304 alkynyl group Chemical group 0.000 claims 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 1
- 125000001506 1,2,3-triazol-5-yl group Chemical group [H]N1N=NC([H])=C1[*] 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862622629P | 2018-01-26 | 2018-01-26 | |
| US201862622626P | 2018-01-26 | 2018-01-26 | |
| US62/622,629 | 2018-01-26 | ||
| US62/622,626 | 2018-01-26 | ||
| JP2020540750A JP7307733B2 (ja) | 2018-01-26 | 2019-01-25 | キナーゼ依存的障害を処置するための化合物 |
| PCT/US2019/015289 WO2019148036A1 (en) | 2018-01-26 | 2019-01-25 | Compounds for the treatment of kinase-dependent disorders |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540750A Division JP7307733B2 (ja) | 2018-01-26 | 2019-01-25 | キナーゼ依存的障害を処置するための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023082042A JP2023082042A (ja) | 2023-06-13 |
| JP2023082042A5 true JP2023082042A5 (enExample) | 2023-09-26 |
| JP7596427B2 JP7596427B2 (ja) | 2024-12-09 |
Family
ID=65409542
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540750A Active JP7307733B2 (ja) | 2018-01-26 | 2019-01-25 | キナーゼ依存的障害を処置するための化合物 |
| JP2023045583A Active JP7596427B2 (ja) | 2018-01-26 | 2023-03-22 | キナーゼ依存的障害を処置するための化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540750A Active JP7307733B2 (ja) | 2018-01-26 | 2019-01-25 | キナーゼ依存的障害を処置するための化合物 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11708367B2 (enExample) |
| EP (1) | EP3743068A1 (enExample) |
| JP (2) | JP7307733B2 (enExample) |
| KR (1) | KR102759973B1 (enExample) |
| CN (1) | CN112312909B (enExample) |
| AU (1) | AU2019212719B2 (enExample) |
| BR (1) | BR112020015199A2 (enExample) |
| CA (1) | CA3088127A1 (enExample) |
| CL (1) | CL2020001930A1 (enExample) |
| CO (1) | CO2020010467A2 (enExample) |
| CR (2) | CR20250117A (enExample) |
| IL (2) | IL276028B2 (enExample) |
| MA (1) | MA51672A (enExample) |
| MX (2) | MX2020007759A (enExample) |
| PE (1) | PE20210044A1 (enExample) |
| PH (1) | PH12020551059A1 (enExample) |
| SA (1) | SA520412488B1 (enExample) |
| SG (1) | SG11202006945PA (enExample) |
| UA (1) | UA128348C2 (enExample) |
| WO (1) | WO2019148036A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20250117A (es) * | 2018-01-26 | 2025-05-09 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355) |
| CN117624045A (zh) * | 2018-01-26 | 2024-03-01 | 埃克塞里艾克西斯公司 | 用于治疗激酶依赖性病症的化合物 |
| WO2019148043A1 (en) | 2018-01-26 | 2019-08-01 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| CN112457308B (zh) | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| CN115244041A (zh) * | 2020-03-10 | 2022-10-25 | 南京明德新药研发有限公司 | 乙烯基取代吡啶类化合物 |
| GB202004960D0 (en) * | 2020-04-03 | 2020-05-20 | Kinsenus Ltd | Inhibitor compounds |
| WO2021222673A1 (en) | 2020-04-30 | 2021-11-04 | Exelixis, Inc. | Processes for the preparation of a kinase inhibitor |
| CA3213079A1 (en) | 2021-04-13 | 2022-10-20 | Kristin Lynne ANDREWS | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN117164527A (zh) * | 2022-05-25 | 2023-12-05 | 大连理工大学 | 一种钒催化杂环芳香腈水解制备杂环芳香酰胺的方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| ATE205483T1 (de) | 1995-03-30 | 2001-09-15 | Pfizer | Chinazolinderivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| ES2174250T5 (es) | 1996-04-12 | 2010-04-21 | Warner-Lambert Company Llc | Inhibidores irreversibles de tirosina quinasas. |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU2004259009A1 (en) | 2003-07-23 | 2005-02-03 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
| CA2744997A1 (en) * | 2003-09-26 | 2005-04-07 | Exelixis, Inc. | C-met modulators and method of use |
| AU2006236508B2 (en) | 2005-04-15 | 2012-02-02 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| JP2009529047A (ja) | 2006-03-07 | 2009-08-13 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環系ピラゾール化合物およびその使用 |
| WO2010045095A1 (en) * | 2008-10-14 | 2010-04-22 | Ning Xi | Compounds and methods of use |
| EP2214019A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| EP2213686A1 (en) | 2009-01-28 | 2010-08-04 | Externautics S.p.A. | Tumor markers and methods of use thereof |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| EP3345920A1 (en) | 2009-10-26 | 2018-07-11 | Externautics S.p.A. | Breast tumor markers and methods of use thereof |
| WO2011051276A1 (en) | 2009-10-26 | 2011-05-05 | Externautics S.P.A. | Colon and rectal tumor markers and methods of use thereof |
| US8921058B2 (en) | 2009-10-26 | 2014-12-30 | Externautics Spa | Prostate tumor markers and methods of use thereof |
| EP2494361B2 (en) | 2009-10-26 | 2019-01-09 | Externautics S.p.A. | Ovary tumor markers and methods of use thereof |
| EP2493916B1 (en) | 2009-10-26 | 2016-06-08 | Externautics S.p.A. | Lung tumor markers and methods of use thereof |
| EP2383578A1 (en) | 2010-04-30 | 2011-11-02 | Externautics S.p.A. | Tumor marker and methods of use thereof |
| ES2598530T3 (es) * | 2010-07-14 | 2017-01-27 | Betta Pharmaceuticals Co., Ltd. | Nuevos derivados heterocíclicos condensados útiles como inhibidores de la tirosina quinasa c-Met |
| US8664244B2 (en) * | 2010-09-12 | 2014-03-04 | Advenchen Pharmaceuticals, LLC | Compounds as c-Met kinase inhibitors |
| CN102093421B (zh) | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| WO2014055897A2 (en) | 2012-10-04 | 2014-04-10 | Dana-Farber Cancer Institute, Inc. | Human monoclonal anti-pd-l1 antibodies and methods of use |
| PT2992017T (pt) | 2013-05-02 | 2021-01-29 | Anaptysbio Inc | Anticorpos dirigidos contra a morte programada 1 (pd-1) |
| EP3008086A2 (en) | 2013-06-14 | 2016-04-20 | Externautics S.p.A. | Tumor marker, monoclonal antibodies and methods of use thereof |
| IL292510A (en) | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| EP3134084B1 (en) | 2014-04-25 | 2021-03-17 | Exelixis, Inc. | Method of treating lung adenocarcinoma |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| CN106279147A (zh) * | 2015-05-21 | 2017-01-04 | 中国科学院上海药物研究所 | 一种吡啶并氮杂环化合物及其制备方法和用途 |
| US20180009758A1 (en) | 2015-06-29 | 2018-01-11 | Ontogenesis, Llc | Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use |
| CN105797123A (zh) | 2016-05-18 | 2016-07-27 | 王超 | 一种治疗不孕不育的中药组合物 |
| CN106400155A (zh) | 2016-08-31 | 2017-02-15 | 飞佛特种纺织品（宁波）有限公司 | 一种防老化阳光面料 |
| CN107235896B (zh) | 2016-09-13 | 2019-11-05 | 上海翔锦生物科技有限公司 | 酪氨酸激酶抑制剂及其应用 |
| SG11202005719UA (en) | 2017-12-20 | 2020-07-29 | Angex Pharmaceutical Inc | Carbamate and urea compounds as multikinase inhibitors |
| CR20250117A (es) * | 2018-01-26 | 2025-05-09 | Exelixis Inc | COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS DEPENDIENTES DE CINASAS (Divisional 2020-0355) |
-
2019
- 2019-01-25 CR CR20250117A patent/CR20250117A/es unknown
- 2019-01-25 UA UAA202005478A patent/UA128348C2/uk unknown
- 2019-01-25 MX MX2020007759A patent/MX2020007759A/es unknown
- 2019-01-25 PE PE2020001120A patent/PE20210044A1/es unknown
- 2019-01-25 CN CN201980021547.0A patent/CN112312909B/zh active Active
- 2019-01-25 MA MA051672A patent/MA51672A/fr unknown
- 2019-01-25 IL IL276028A patent/IL276028B2/en unknown
- 2019-01-25 CR CR20200355A patent/CR20200355A/es unknown
- 2019-01-25 EP EP19704968.7A patent/EP3743068A1/en active Pending
- 2019-01-25 WO PCT/US2019/015289 patent/WO2019148036A1/en not_active Ceased
- 2019-01-25 KR KR1020207024577A patent/KR102759973B1/ko active Active
- 2019-01-25 CA CA3088127A patent/CA3088127A1/en active Pending
- 2019-01-25 SG SG11202006945PA patent/SG11202006945PA/en unknown
- 2019-01-25 AU AU2019212719A patent/AU2019212719B2/en active Active
- 2019-01-25 US US16/964,228 patent/US11708367B2/en active Active
- 2019-01-25 BR BR112020015199-8A patent/BR112020015199A2/pt active Search and Examination
- 2019-01-25 JP JP2020540750A patent/JP7307733B2/ja active Active
-
2020
- 2020-07-09 PH PH12020551059A patent/PH12020551059A1/en unknown
- 2020-07-22 MX MX2022014351A patent/MX2022014351A/es unknown
- 2020-07-23 SA SA520412488A patent/SA520412488B1/ar unknown
- 2020-07-23 CL CL2020001930A patent/CL2020001930A1/es unknown
- 2020-08-25 CO CONC2020/0010467A patent/CO2020010467A2/es unknown
-
2023
- 2023-03-22 JP JP2023045583A patent/JP7596427B2/ja active Active
- 2023-05-03 IL IL302626A patent/IL302626B2/en unknown
- 2023-06-13 US US18/334,113 patent/US12195475B2/en active Active